Found 9 matching trials
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma PHASE1 The main objective of this study is to assess safety, tolerability, and pha...
Show More Location
The University of Chicago Medical Center /ID# 217196
Learn More & Join Trial
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma PHASE2 Currently, there is no widely used adjuvant treatment available to improve ...
Show More Location
VU Medical Centere
Learn More & Join Trial
A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma PHASE2 The goal of the Phase 1 study was to find the recommended Phase 2 dose of t...
Show More Location
The University of Arizona Cancer Center
Learn More & Join Trial
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors PHASE1 This is a Phase 1b study that incorporates dose expansion cohorts to furthe...
Show More Location
Scottsdale Healthcare Hospitals DBA Honor Health
Learn More & Join Trial
Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients PHASE1 Phase 1, randomized, double-blind, placebo-controlled, dose-escalation stud...
Show More Location
Multiple Locations
Learn More & Join Trial
Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers PHASE1 Open label, phase Ib study of intratumoral tilsotolimod in combination with...
Show More Learn More & Join Trial
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) PHASE2 A Phase 2 study intended to see efficacy of tilsotolimod in combination wit...
Show More Status
Active Not Recruiting
Location
Banner University Medical Center Tucson Campus
Learn More & Join Trial
A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma PHASE3 A Phase 3 comparison of ipilimumab with and without IMO-2125 in advanced me...
Show More Location
University of Alabama at Birmingham (UAB)
Learn More & Join Trial
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients PHASE1 First-in-humans, phase 1, dose-escalation study with 4 dose levels of singl...
Show More Location
University of Colorado Hospital
Learn More & Join Trial